<VariationArchive VariationID="1073697" VariationName="NM_000156.6(GAMT):c.307del (p.Ala103fs)" VariationType="Deletion" Accession="VCV001073697" Version="6" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-28" DateCreated="2021-05-10" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1064664" VariationID="1073697">
      <GeneList>
        <Gene Symbol="GAMT" FullName="guanidinoacetate N-methyltransferase" GeneID="2593" HGNC_ID="HGNC:4136" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1397026" stop="1401542" display_start="1397026" display_stop="1401542" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1397024" stop="1401568" display_start="1397024" display_stop="1401568" Strand="-" />
          </Location>
          <OMIM>601240</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000156.6(GAMT):c.307del (p.Ala103fs)</Name>
      <CanonicalSPDI>NC_000019.10:1399812:CCC:CC</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="1399813" stop="1399813" display_start="1399813" display_stop="1399813" variantLength="1" positionVCF="1399812" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="1399812" stop="1399812" display_start="1399812" display_stop="1399812" variantLength="1" positionVCF="1399811" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>A103fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.1399815del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.1399815del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_138924.3" sequenceAccession="NM_138924" sequenceVersion="3" change="c.307del">
            <Expression>NM_138924.3:c.307del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_620279.1" sequenceAccession="NP_620279" sequenceVersion="1" change="p.Ala103fs">
            <Expression>NP_620279.1:p.Ala103fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.1399814del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.1399814del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009785.1" sequenceAccession="NG_009785" sequenceVersion="1" change="g.6741del">
            <Expression>NG_009785.1:g.6741del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000156.6" sequenceAccession="NM_000156" sequenceVersion="6" change="c.307del" MANESelect="true">
            <Expression>NM_000156.6:c.307del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000147.1" sequenceAccession="NP_000147" sequenceVersion="1" change="p.Ala103fs">
            <Expression>NP_000147.1:p.Ala103fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2082622867" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000156.6(GAMT):c.307del (p.Ala103fs) AND Cerebral creatine deficiency syndrome" Accession="RCV001386769" Version="4">
        <ClassifiedConditionList TraitSetID="16862">
          <ClassifiedCondition DB="MedGen" ID="C5244016">Cerebral creatine deficiency syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-08-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000156.6(GAMT):c.307del (p.Ala103fs) AND Deficiency of guanidinoacetate methyltransferase" Accession="RCV002504647" Version="1">
        <ClassifiedConditionList TraitSetID="2278">
          <ClassifiedCondition DB="MedGen" ID="C0574080">Deficiency of guanidinoacetate methyltransferase</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-08-14" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-24" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2021-05-10" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15108290</ID>
        </Citation>
        <DescriptionHistory Dated="2022-12-31">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="16862" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16661" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Creatine deficiency syndromes</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Cerebral creatine deficiency syndrome</ElementValue>
                <XRef ID="MONDO:0000456" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">CDS</ElementValue>
                <XRef ID="79172" DB="Orphanet" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">CCAD</ElementValue>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18952" />
                <XRef ID="18952" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <XRef ID="79172" DB="Orphanet" />
              <XRef ID="C5244016" DB="MedGen" />
              <XRef ID="MONDO:0000456" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS300352" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2278" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2252" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CEREBRAL CREATINE DEFICIENCY SYNDROME 2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0002" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601240.0008" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Deficiency of guanidinoacetate methyltransferase</ElementValue>
                <XRef ID="Guanidinoacetate+Methyltransferase+Deficiency/3202" DB="Genetic Alliance" />
                <XRef ID="124239003" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CCDS2</ElementValue>
                <XRef Type="MIM" ID="612736" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The creatine deficiency disorders (CDDs), inborn errors of creatine metabolism and transport, comprise three disorders: the creatine biosynthesis disorders guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency; and creatine transporter (CRTR) deficiency. Developmental delay and cognitive dysfunction or intellectual disability and speech-language disorder are common to all three CDDs. Onset of clinical manifestations of GAMT deficiency (reported in ~130 individuals) is between ages three months and two years; in addition to developmental delays, the majority of individuals have epilepsy and develop a behavior disorder (e.g., hyperactivity, autism, or self-injurious behavior), and about 30% have movement disorder. AGAT deficiency has been reported in 16 individuals; none have had epilepsy or movement disorders. Clinical findings of CRTR deficiency in affected males (reported in ~130 individuals) in addition to developmental delays include epilepsy (variable seizure types and may be intractable) and behavior disorders (e.g., attention deficit and/or hyperactivity, autistic features, impulsivity, social anxiety), hypotonia, and (less commonly) a movement disorder. Poor weight gain with constipation and prolonged QTc on EKG have been reported. While mild-to-moderate intellectual disability is commonly observed up to age four years, the majority of adult males with CRTR deficiency have been reported to have severe intellectual disability. Females heterozygous for CRTR deficiency are typically either asymptomatic or have mild intellectual disability, although a more severe phenotype resembling the male phenotype has been reported.</Attribute>
                <XRef ID="NBK3794" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2578" />
                <XRef ID="2578" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301745</ID>
                <ID Source="BookShelf">NBK3794</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Increased Guanidinoacetate, Guanidinoacetate Methyltransferase Deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/GAMT-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Algorithm, GAMT Deficiency: Elevated Guanidinoacetate, 2022</CitationText>
              </Citation>
              <XRef ID="382" DB="Orphanet" />
              <XRef ID="C0574080" DB="MedGen" />
              <XRef ID="MONDO:0012999" DB="MONDO" />
              <XRef Type="MIM" ID="612736" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3112772" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="10476027|MedGen:CN227588" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001587117" DateUpdated="2024-02-28" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15108290</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1073697). This variant has not been reported in the literature in individuals affected with GAMT-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ala103Profs*11) in the GAMT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAMT are known to be pathogenic (PMID: 15108290).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAMT" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.1399812del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN227588" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5459570" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000156.6:c.307del|OMIM:612736" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002811119" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000156.6:c.307del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612736" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3112772" TraitType="Disease" MappingType="XRef" MappingValue="CN227588" MappingRef="MedGen">
        <MedGen CUI="C5244016" Name="Cerebral creatine deficiency syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5459570" TraitType="Disease" MappingType="XRef" MappingValue="612736" MappingRef="OMIM">
        <MedGen CUI="C0574080" Name="Deficiency of guanidinoacetate methyltransferase" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

